MDR1基因产物在非小细胞肺癌中的表达研究

目的探讨ＭＤＲ１基因表达产物Ｐ－糖蛋白（Ｐ－ｇｐ）在非小细胞肺癌中的表达水平及其临床意义。方法采用免疫组织化学标记链亲和素－生物素法检测１２６例非小细胞肺癌标本中Ｐ－ｇｐ的表达。结果（１）Ｐ－ｇｐ总的阳性表达率为５６．３％（７１／１２６）；（２）腺癌与鳞癌之间，鳞癌与腺鳞癌之间Ｐ－ｇｐ的表达阳性率无显著差异（Ｐ＞０．０５），但腺鳞癌Ｐ－ｇｐ的阳性表达率高于腺癌（Ｐ＜０．０５）；（３）Ｐ－ｇｐ的表达与性别、年龄、肿瘤生长部位、病理分期及是否伴有淋巴结转移无关。结论Ｐ－ｇｐ在非小细胞肺癌中有较高的阳性表达率，且与病理类型有一定关系，提示在非小细胞肺癌尤其是Ｐ－ｇｐ高度表达类型肺癌的化疗中，应重视Ｐ－ｇｐ介导的多药耐药性。

Study on Expression of MDR 1 Gene Product in Non small Cell Lung Cancer

Objective To explore the expression level and its clinical significance of MDR 1 gene product, the P glycoprotein (P gp) in non small cell lung cancer. Methods Results (1) 71 (56.3%) out of the 126 NSCLC were positive for the P gp expression. (2) No significant difference was found between adenocarcinoma and squamous carcinoma of NSCLC in P gp expression ( P>0.05) , as same as the squamous carcinoma and adenosquamous carcinoma. P gp positive expression of adenosquamous carcinoma was significantly higher than that of the adenocarcinoma ( P <0.05). (3) The positive expression of P gp were not correlated to the sexes, ages, location of tumor occuring, stages of the tumor, and with or without lymph node metastasis ( P> 0.05) . Conclusion The positive expression of P gp is higher in NSCLC and correlated to the pathological patterns in some degree. It is suggested that multidrug resistance induced by overexpression of P gp should be considered for the NSCLC undertaking chemotherapy, especially for the pathological patterns with higher P gp positive expression.